Luken Investment Analytics LLC Lowers Stake in CVS Health Co. (NYSE:CVS)

Luken Investment Analytics LLC lessened its position in shares of CVS Health Co. (NYSE:CVS) by 6.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,274 shares of the pharmacy operator’s stock after selling 290 shares during the period. Luken Investment Analytics LLC’s holdings in CVS Health were worth $337,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Bryn Mawr Capital Management LLC boosted its position in shares of CVS Health by 74.0% in the third quarter. Bryn Mawr Capital Management LLC now owns 43,213 shares of the pharmacy operator’s stock worth $3,017,000 after buying an additional 18,385 shares during the period. Value Partners Investments Inc. boosted its position in shares of CVS Health by 26.5% in the third quarter. Value Partners Investments Inc. now owns 991,601 shares of the pharmacy operator’s stock worth $69,261,000 after buying an additional 207,702 shares during the period. Sonora Investment Management Group LLC boosted its position in shares of CVS Health by 1.6% in the third quarter. Sonora Investment Management Group LLC now owns 50,488 shares of the pharmacy operator’s stock worth $3,525,000 after buying an additional 774 shares during the period. Checchi Capital Advisers LLC boosted its position in shares of CVS Health by 2.3% in the third quarter. Checchi Capital Advisers LLC now owns 10,405 shares of the pharmacy operator’s stock worth $726,000 after buying an additional 233 shares during the period. Finally, Personal CFO Solutions LLC boosted its position in shares of CVS Health by 2.6% in the third quarter. Personal CFO Solutions LLC now owns 19,355 shares of the pharmacy operator’s stock worth $1,351,000 after buying an additional 491 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of analyst reports. HSBC initiated coverage on CVS Health in a report on Friday, December 22nd. They issued a “buy” rating and a $94.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $87.00 price target on shares of CVS Health in a report on Wednesday, April 10th. Leerink Partnrs reissued an “outperform” rating on shares of CVS Health in a report on Monday, February 26th. Piper Sandler increased their price target on CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Finally, StockNews.com cut CVS Health from a “buy” rating to a “hold” rating in a research note on Thursday, February 15th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.44.

CVS Health Stock Performance

NYSE CVS traded up $0.45 during trading hours on Thursday, reaching $69.05. The company’s stock had a trading volume of 3,561,992 shares, compared to its average volume of 10,806,943. The company has a current ratio of 0.86, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77. The business has a 50-day simple moving average of $75.53 and a 200 day simple moving average of $73.73. CVS Health Co. has a 52 week low of $64.41 and a 52 week high of $83.25. The stock has a market cap of $87.04 billion, a PE ratio of 10.71, a PEG ratio of 0.91 and a beta of 0.52.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The firm had revenue of $93.81 billion for the quarter, compared to analysts’ expectations of $90.58 billion. During the same quarter last year, the company posted $1.99 earnings per share. CVS Health’s revenue was up 11.9% on a year-over-year basis. Equities research analysts predict that CVS Health Co. will post 8.32 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be issued a dividend of $0.665 per share. The ex-dividend date is Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.85%. CVS Health’s dividend payout ratio (DPR) is presently 41.18%.

Insider Activity

In other news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the sale, the executive vice president now owns 39,765 shares of the company’s stock, valued at $3,059,916.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.24% of the company’s stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.